BioCina completes takeover of Pfizer-owned Australia plant; Cambrex adds space at NC site for small molecules
San Diego CDMO BioCina has finalized the final transition of its takeover of an Australian manufacturing site to boost its mRNA operations.
BioCina completed the acquisition from Pfizer-owned Hospira Adelaide, which began in August 2020. It now will have the ability to quickly manufacture therapies using plasmid DNA, a critical part of manufacturing mRNA vaccines, CAR-T cell therapies and viral gene replacement therapies.
In a statement, BioCina CEO Ian Wisenberg said:
Our vision is to be a trusted CDMO partner to the biopharma industry that helps save the lives of patients worldwide. We are now in full flight with unfettered ability to provide superior development and manufacturing services. With the current global pandemic, we have seen the need to develop fast, innovative life-saving medicines with world class science and superior quality to our partnered clients. This is at the core of the BioCina team’s capability, experience and passion.
The move is part of Australia’s larger commitment to the life sciences industry on the continent. Its government has a plan in place to double the industry’s contribution to the economy from $2.3 billion to $5 billion.
The announcement comes as the country is in the middle of its worst Covid-19 outbreak ever. There were 2,391 new cases on Oct. 5, a number that seems to be on the rise still. Vaccination efforts are on the rise, as 67% of Australians have received at least one dose, more nearly doubling the number of vaccinated citizens since Aug. 1.
Small molecule manufacture expands at NC campus
A manufacturer has become the latest to expand its operations in North Carolina’s Research Triangle this year.
Cambrex announced it will spend another $30 million to hire 78 employees and expand production at its High Point campus.
“We are excited to celebrate Cambrex’s expansion on National Manufacturing Day,” said Gov. Roy Cooper. “When thriving pharmaceutical companies continue making life-changing medicines in North Carolina, it validates our reputation as a place where life science companies can flourish and do groundbreaking work.”
The company, based in East Rutherford, NJ, already finished a $30 million expansion that added 78 jobs once before, bringing its number of employees to 150. The site makes active pharmaceutical ingredients and supports clinical trials from Phase I through Phase III.
Merck Pennsylvania site to make J&J jabs for Europe
The EMA has authorized another Merck site for the production of J&J’s Covid-19 vaccine.
West Point, PA will manufacture the finished vaccine product to help support the supply of the vaccine to the country. Because the site doesn’t require a European Commission decision, it can become operational immediately.